Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cash from Investing Activities (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Cash from Investing Activities over the past 3 years, most recently at -$1.0 million for Q4 2025.

  • Quarterly results put Cash from Investing Activities at -$1.0 million for Q4 2025, down 33933.33% from a year ago — trailing twelve months through Dec 2025 was -$4.5 million (down 3673.33% YoY), and the annual figure for FY2025 was -$4.5 million, down 3673.33%.
  • Cash from Investing Activities for Q4 2025 was -$1.0 million at Tonix Pharmaceuticals Holding, down from -$962000.0 in the prior quarter.
  • Over the last five years, Cash from Investing Activities for TNXP hit a ceiling of -$3000.0 in Q4 2024 and a floor of -$24.0 million in Q2 2023.
  • Median Cash from Investing Activities over the past 3 years was -$821000.0 (2023), compared with a mean of -$3.1 million.
  • Biggest five-year swings in Cash from Investing Activities: skyrocketed 99.3% in 2024 and later crashed 33933.33% in 2025.
  • Tonix Pharmaceuticals Holding's Cash from Investing Activities stood at -$431000.0 in 2023, then skyrocketed by 99.3% to -$3000.0 in 2024, then crashed by 33933.33% to -$1.0 million in 2025.
  • The last three reported values for Cash from Investing Activities were -$1.0 million (Q4 2025), -$962000.0 (Q3 2025), and -$2.5 million (Q2 2025) per Business Quant data.